145643-10-3

Upstream product

• 623-00-7 4-bromobenzenecarbonitrile 
• 591-80-0 pent-4-enoic acid 
• 183671-17-2 5-(p-cyanophenyl)-4-pentenoic acid 
• 145643-09-0 5-(p-cyanophenyl)-4-pentenoic acid 

Downstream Products

• 147524-70-7 DL-N-[5-(p-Cyanophenyl)pentanoyl]-3-phenyl-beta-alanine 
• 152151-37-6 5-[4-(aminoiminomethyl)phenyl]pentanoic acid 
• 145643-12-5 (S)-N-((S)-1-tert-Butoxycarbonyl-2-phenyl-ethyl)-3-[5-(4-thiocarbamoyl-phenyl)-pentanoylamino]-succinamic acid tert-butyl ester 
• 145643-14-7 (S)-N-((S)-1-tert-Butoxycarbonyl-2-phenyl-ethyl)-3-[5-(4-carbamimidoyl-phenyl)-pentanoylamino]-succinamic acid tert-butyl ester 
• 145643-15-8 5-(p-amidinophenyl)pentanoyl-(S)-aspartyl-(S)-phenylalanine 
• 145643-11-4 5-(p-cyanophenyl)pentanoyl-(S)-aspartyl(O-tert-butyl)-(S)-phenylalanine(O-tert-butyl) 

Relevant academic research and scientific papers

2,3-diaminopropionic acid derivative

The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): STR1 or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.

Phenyl amidines derivatives useful as platelet aggregation inhibitors

This invention relates to phenyl amidine derivatives having the following formula STR1 or a pharmaceutically acceptable salt which are useful in the inhibition of platelet aggregation. This invention also relates to pharmaceutical compositions of such phe

Phenyl amidines lactones useful as platelet aggregation inhibitors

This invention relates to compounds having the following formula STR1 wherein Z is a lactone or a lactone which is fused to a benzene ring which are useful in the inhibition of platelet aggregation. This invention also relates to pharmaceutical compositio

Peptide mimetic compounds useful as platelet aggregation inhibitors

This invention relates to compounds having the following formula STR1 or a pharmaceutically acceptable salt which are useful in the inhibition of platelet aggregation. This invention also relates to pharmaceutical compositions--of such phenyl amidines der

Platelet aggregation inhibitors

This invention relates to compounds having the following formula STR1 or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions including the compounds, and to a method of inhi

Peptide mimetic compounds useful as platelet aggregation inhibitors

This invention relates to having the following formula STR1 or a pharmaceutically acceptable salt which are useful in the inhibition of platelet aggregation. This invention also relates to pharmaceutical compositions of such phenyl amidines derivatives.

Platelet aggregation inhibitors

This invention relates to compounds having the following formula STR1 or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions including the compounds and to a method of inhib

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor

Peptide mimetics of the RGDF sequence in which Arg-Gly has been replaced with 5-(4-amidinophenyl)pentanoyl mimetic has led to a 1000-fold increase in inhibitory potency over the natural RGDF ligand. The guanidine residue of the arginine may be involved in